ERBB2 and breast cancer: Furthermore, recent results suggested that in PIK3CA or HER2-mutant breast cancers, loss of PTEN was a driver of resistance to p110α-targeting strategies through the maintenance of PI3K signaling by alternative p110 isoforms33.